clinical trial · NCT06618235
Trial of THEO-260 in Ovarian Cancer Patients
Theolytics Limited·phase2·recruiting·n = 44
Ovarian CancerTHEO-260
brief summary
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
started
Sep 24, 2024
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Apr 14, 2026
official title
A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol